Hanson Pharmaceuticals announced on the Hong Kong Stock Exchange today that its wholly-owned subsidiary, Hansoh Bio, LLC, and F. Hoffmann-La Roche Ltd have entered into a strategic cooperation and licensing agreement. This strategic cooperation covers a combination of antibody-drug conjugate projects, including two Hanson preclinical ADC projects, and multiple ADC projects developed with targets proposed by Roche and based on Hanson's own ADC technology platform. Hanson will receive a down payment of US$400 million and a first anniversary payment of US$110 million, and will be eligible to collect milestone payments of potentially over US$15 billion based on the development, registration and commercialization of such projects, as well as tiered royalties based on future potential product sales.

Hanson Pharmaceuticals announced on the Hong Kong Stock Exchange today that its wholly-owned subsidiary, Hansoh Bio, LLC, and F. Hoffmann-La Roche Ltd have entered into a strategic cooperation and licensing agreement. This strategic cooperation covers a combination of antibody-drug conjugate projects, including two Hanson preclinical ADC projects, and several ADC projects developed with targets proposed by Roche and based on Hanson's own ADC technology platform. Hanson will receive a down payment of US$400 million and a first anniversary payment of US$110 million, and will be eligible to collect milestone payments of potentially over US$15 billion based on the development, registration and commercialization of such projects, as well as tiered royalties based on future potential product sales.